Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Metabolic & GLP-1/GIP Agonists

Tirzepatide

Also known as: Mounjaro Zepbound

Evidence: Strong clinical Disclaimer: Standard FDA-approved

Mechanism & research context

Dual GLP-1/GIP receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

FDA-approved indication: Type 2 diabetes (Mounjaro); chronic weight management (Zepbound).

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Tirzepatide

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT03940742 PHASE1 COMPLETED

    A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment

    Condition: Hepatic Insufficiency

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT03954834 PHASE3 COMPLETED

    A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

    Condition: Type 2 Diabetes Mellitus

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT04039503 PHASE3 COMPLETED

    Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

    Condition: Type 2 Diabetes

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05696847 PHASE1 COMPLETED

    A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity

    Condition: Obesity

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05822830 PHASE3 COMPLETED

    A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities

    Condition: Obesity; Overweight

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05963022 PHASE3 COMPLETED

    A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes

    Condition: Type 2 Diabetes

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06246799 PHASE3 RECRUITING

    Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes

    Condition: Type 2 Diabetes (Adult Onset)

    Sponsor: The University of Texas Health Science Center at San Antonio

    Open on ClinicalTrials.gov ↗
  • NCT06630585 PHASE3 RECRUITING

    GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes: A Prospective, Randomized, Clinical Study - The AID-JUNCT Trial

    Condition: Type 1 Diabetes (T1D)

    Sponsor: University of Bern

    Open on ClinicalTrials.gov ↗
  • NCT06635057 PHASE4 ACTIVE_NOT_RECRUITING

    A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan

    Condition: Type 2 Diabetes

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06774079 PHASE4 RECRUITING

    A Randomized Clinical Trial to Determine the Effect of Dual Glucose-dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonist-mediated Weight Loss and Diet on Crohn's Disease Clinical Response: a Pilot Study

    Condition: Crohn Disease

    Sponsor: University of Miami

    Open on ClinicalTrials.gov ↗
  • NCT06779929 ACTIVE_NOT_RECRUITING

    Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    Condition: Type 2 Diabetes

    Sponsor: Brigham and Women's Hospital

    Open on ClinicalTrials.gov ↗
  • NCT06802081 PHASE2 RECRUITING

    TIRO-AF: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

    Condition: Atrial Fibrillation; Obesity

    Sponsor: The Cleveland Clinic

    Open on ClinicalTrials.gov ↗
  • NCT06857942 PHASE4 RECRUITING

    A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice

    Condition: Psoriasis; Overweight or Obesity

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06918405 PHASE3 ACTIVE_NOT_RECRUITING

    Efficacy and Safety of Tirzepatide for Weight Management in Overweight or Obese Adult Individuals With or Without Type 2 Diabetes Mellitus: A Real-World Study in Bangladesh

    Condition: Obesity and Obesity-related Medical Conditions

    Sponsor: Chittagong Medical College

    Open on ClinicalTrials.gov ↗
  • NCT06962280 PHASE3 ACTIVE_NOT_RECRUITING

    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Condition: Type 1 Diabetes; Obesity; Overweight

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT07226947 NA RECRUITING

    BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)

    Condition: Obesity; Body Composition

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT07303556 NA ACTIVE_NOT_RECRUITING

    Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs

    Condition: Heart Failure; Diabete Type 2; Arterial Hypertension

    Sponsor: Nazarbayev University

    Open on ClinicalTrials.gov ↗
  • NCT07354880 PHASE4 NOT_YET_RECRUITING

    Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

    Condition: Obesity & Overweight; Adult Congenital Heart Disease

    Sponsor: University Medical Centre Ljubljana

    Open on ClinicalTrials.gov ↗
  • NCT07382024 NA NOT_YET_RECRUITING

    Efficacy of Tirzepatide on Weight Loss and Atrial Fibrillation Burden After Catheter Ablation in Overweight or Obese Patients

    Condition: Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight

    Sponsor: National Taiwan University Hospital

    Open on ClinicalTrials.gov ↗
  • NCT07555730 PHASE4 NOT_YET_RECRUITING

    Effect of AI-assisted Multi-domain Lifestyle Intervention Versus Tirzepatide Treatment on Weight Loss Maintenance in Adults With Type 2 Diabetes: a Randomized Clinical Trial.

    Condition: Overweight or Obesity; Type 2 Diabetes; Weight Loss Maintenance

    Sponsor: Huazhong University of Science and Technology

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Tirzepatide yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Tirzepatide, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Tirzepatide. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.